Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TRVI Stock Forecast 2025-2026
$6.60
Current Price
$671.52M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TRVI Price Targets
+339.4%
To High Target of $29.00
+203.0%
To Median Target of $20.00
+66.7%
To Low Target of $11.00
TRVI Price Momentum
-4.3%
1 Week Change
+18.7%
1 Month Change
+141.8%
1 Year Change
+51.4%
Year-to-Date Change
-10.7%
From 52W High of $7.39
+187.0%
From 52W Low of $2.30
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Trevi Therapeutics (TRVI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TRVI and similar high-potential opportunities.
Latest TRVI Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, TRVI has a bullish consensus with a median price target of $20.00 (ranging from $11.00 to $29.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $6.60, the median forecast implies a 203.0% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ryan Deschner at Raymond James, projecting a 339.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TRVI Analyst Ratings
9
Buy
0
Hold
0
Sell
TRVI Price Target Range
Low
$11.00
Average
$20.00
High
$29.00
Current: $6.60
Latest TRVI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TRVI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $24.00 |
| Mar 19, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $12.50 |
| Mar 19, 2025 | Needham | Serge Belanger | Buy | Maintains | $24.00 |
| Mar 19, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $20.00 |
| Mar 11, 2025 | Oppenheimer | Leland Gershell | Outperform | Maintains | $20.00 |
| Mar 10, 2025 | Raymond James | Ryan Deschner | Strong Buy | Upgrade | $29.00 |
| Mar 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
| Mar 10, 2025 | Needham | Serge Belanger | Buy | Maintains | $25.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $12.50 |
| Mar 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
| Feb 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
| Jan 8, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
| Dec 16, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
| Dec 13, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $7.50 |
| Dec 12, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $7.50 |
| Dec 12, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
| Dec 12, 2024 | Needham | Serge Belanger | Buy | Reiterates | $8.00 |
| Dec 4, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $21.00 |
| Dec 4, 2024 | Needham | Serge Belanger | Buy | Reiterates | $8.00 |
Trevi Therapeutics Inc. (TRVI) Competitors
The following stocks are similar to Trevi Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TRVI
Trevi Therapeutics
mkt cap
638.10M
Trevi Therapeutics Inc. (TRVI) Financial Data
Trevi Therapeutics Inc. has a market capitalization of $671.52M with a P/E ratio of -14.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -55.1%.
Valuation Metrics
Market Cap
$671.52M
Enterprise Value
$569.22M
P/E Ratio
-14.2x
PEG Ratio
-13.8x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+15.4%
Current Ratio
15.4x
Debt/Equity
1.0x
ROE
-55.1%
ROA
-34.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Trevi Therapeutics Inc. (TRVI) Business Model
About Trevi Therapeutics Inc.
What They Do
Develops therapies for serious neurological conditions.
Business Model
The company focuses on developing and commercializing treatments for central nervous system disorders with significant unmet medical needs. Trevi Therapeutics generates revenue through the advancement of its product candidates, particularly an investigational therapy for chronic pruritus, through clinical trials and eventual commercialization.
Additional Information
Headquartered in New Haven, Connecticut, Trevi Therapeutics is dedicated to addressing niche medical challenges and aims to create new standards in treating persistent neurological symptoms, contributing to broader advancements in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
26
CEO
Ms. Jennifer L. Good
Country
United States
IPO Year
2019
Website
www.trevitherapeutics.comTrevi Therapeutics Inc. (TRVI) Latest News & Analysis
Latest News
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
3 days ago
Quick Summary
Enrollment and last visits in the Phase 2b CORAL trial for IPF patients are complete, with topline results expected in Q2 2025. Positive results announced from Phase 2a RIVER trial.
Why It Matters
Positive trial results and upcoming data announcements can influence stock prices, indicating potential growth or setbacks for the company in the competitive pharmaceutical market.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A conference call and webcast is scheduled for 4:30 p.m. ET in New Haven, Conn. Investors may find relevant updates or insights during this event.
Why It Matters
The timing of the conference call may indicate key announcements or financial updates that could influence stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Trevi Therapeutics (Nasdaq: TRVI) will participate in investor conferences in April. The company is developing Haduvio™ for chronic cough related to IPF and RCC.
Why It Matters
Trevi Therapeutics' participation in investor conferences signals potential interest in its therapeutic developments, which could impact stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Trevi Therapeutics, Inc. (NASDAQ:TRVI) will host its Q4 2024 earnings conference call on March 18, 2025, at 4:30 PM ET with key executives and analysts participating.
Why It Matters
Trevi Therapeutics' earnings call provides insights into its financial health and future strategies, crucial for assessing investment potential and market performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
1 month ago
Quick Summary
The company announced positive Phase 2a data for Haduvio in refractory chronic cough and completed enrollment in the Phase 2b CORAL trial, with topline results due in Q2 2025. Ended 2024 with $107.6M in cash.
Why It Matters
Positive trial results for Haduvio in chronic cough could boost its market potential and valuation. Strong cash position extends operational runway, indicating financial stability and growth prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A conference call and webcast is scheduled for 8:30 a.m. ET in New Haven, Connecticut.
Why It Matters
The scheduled conference call and webcast may indicate upcoming financial results or strategic updates, affecting stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TRVI Stock
What is Trevi Therapeutics Inc.'s (TRVI) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Trevi Therapeutics Inc. (TRVI) has a median price target of $20.00. The highest price target is $29.00 and the lowest is $11.00.
Is TRVI stock a good investment in 2025?
According to current analyst ratings, TRVI has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TRVI stock?
Wall Street analysts predict TRVI stock could reach $20.00 in the next 12 months. This represents a 203.0% increase from the current price of $6.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Trevi Therapeutics Inc.'s business model?
The company focuses on developing and commercializing treatments for central nervous system disorders with significant unmet medical needs. Trevi Therapeutics generates revenue through the advancement of its product candidates, particularly an investigational therapy for chronic pruritus, through clinical trials and eventual commercialization.
What is the highest forecasted price for TRVI Trevi Therapeutics Inc.?
The highest price target for TRVI is $29.00 from Ryan Deschner at Raymond James, which represents a 339.4% increase from the current price of $6.60.
What is the lowest forecasted price for TRVI Trevi Therapeutics Inc.?
The lowest price target for TRVI is $11.00 from at , which represents a 66.7% increase from the current price of $6.60.
What is the overall TRVI consensus from analysts for Trevi Therapeutics Inc.?
The overall analyst consensus for TRVI is bullish. Out of 11 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are TRVI stock price projections?
Stock price projections, including those for Trevi Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 2:16 PM UTC